[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) – Form 4 filing (07/02/2025)

Chief Information Officer Kumud Kalia reported routine equity transactions tied to the vesting of previously granted restricted stock units (RSUs) on July 1 2025:

• 2,691 common shares were issued upon the automatic conversion of RSUs (Transaction Code M) at a zero exercise price.
• 1,365 shares were simultaneously surrendered to the company to cover statutory tax-withholding obligations (Transaction Code F) at a market price of $50.71.
• After the net share settlement, Kalia’s direct ownership increased by 1,326 shares to a total of 20,500 common shares.

The derivative table shows that the executive still holds 8,035 unvested RSUs from a November 7 2022 grant and 5,419 unvested RSUs from a December 13 2023 grant, each vesting quarterly over their remaining terms. No open-market sales or purchases were reported beyond the withheld shares, indicating that the insider retained all newly vested stock net of taxes.

This filing reflects standard equity-compensation activity; it does not disclose any new option grants, cash transactions, or information that would materially alter Guardant Health’s financial outlook. The scale of the net acquisition is immaterial relative to the company’s total shares outstanding, but it modestly increases insider alignment.

Insights

Securities Analyst

TL;DR: Routine RSU vesting; insider nets 1,326 GH shares, no market sales—neutral impact.

The Form 4 shows standard quarterly RSU vesting for CIO Kumud Kalia. He received 2,691 shares at zero cost and forfeited 1,365 shares for taxes, ending with 20,500 directly held shares. Remaining unvested RSUs (13,454 total) continue to vest, suggesting future similar filings. There were no discretionary open-market transactions, so the filing offers limited insight into management’s valuation view or imminent corporate developments. Given Guardant Health’s ~105 million shares outstanding, the net issuance is de minimis (<0.002% of float) and unlikely to influence liquidity or valuation. Overall signal: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		M		1,607	A	$0	20,781	D
Common Stock	07/01/2025		M		1,084	A	$0	21,865	D
Common Stock	07/01/2025		F		1,365(1)	D	$50.71	20,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/01/2025		M			1,607	(2)	(3)	Common Stock	1,607	$0	8,035	D
Restricted Stock Units	$0	07/01/2025		M			1,084	(4)	(3)	Common Stock	1,084	$0	5,419	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.